A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Vixarelimab in Participants With Moderate to Severe Ulcerative Colitis (UC)
Stopped Based on a futility analysis, which suggested that the Moonglow study was unlikely to meet its primary endpoint.
Conditions
Interventions
- DRUG: Vixarelimab
- DRUG: Placebo
Sponsor
Genentech, Inc.